View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
May 23, 2022

Precision and personalized medicine: deals decreased significantly in clinical trials in H2 2021

Deals relating to precision and personalized medicine have seen a decrease of 54.1% from H2 2020 to H2 2021.

By Data Journalism Team

In the second half of 2021 the number of deals relating to precision and personalized medicine decreased significantly by 54.1% from the same period in 2020.

This marks an acceleration in growth from the 86.7% decrease in deals that occurred in H1 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During second half of 2021, deals relating to precision and personalized medicine accounted for 6.3% of all deals taking place in the sector. This represents a decrease from the figure of 10.8% in second half of 2020.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which precision and personalized medicine is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena